Hiantis is a young company aiming to bring innovative products and services in the fields of HPV related cancer, dermatology and bone metabolism for the personalized care of patients and their disease.
At present we are focused on the development and clinical validation of a new more predictive molecular HPV test, able to detect the viral load of oncogenic high-risk types, with funding from the European Union’s – Horizon 2020 Research and Innovation Programme under Grant Agreement No 806551. This SME Instrument Phase 2 project is being carried out in collaboration with GeneFirst (UK) as from the 1st of September 2018.
SAMPLE ADEQUACY ASSESSMENT
FULL GENOTYPING HIGH-RISK HPV ASSAY
IMPROVED CLINICAL SPECIFICITY
Suspendisse sed lorem nec dolor consequat aliquam. Morbi tempus est eu quam porttitor, id rutrum metus commodo. Ut sit amet quam eget erat mollis sagittis eu at urna. Integer a massa ex. Maecenas porta feugiat massa non auctor. Vivamus sit amet augue nunc. Donec in tempor nisl. Ut pellentesque purus a lacus congue, sed porta enim consequat.
Discover The Future
We are a multi-disciplinary laboratory committed to focussed and efficient drug discovery